Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18628297 | 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE | April 2024 | October 2025 | Allow | 19 | 1 | 0 | No | No |
| 18621580 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | March 2024 | December 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18620897 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | March 2024 | March 2026 | Abandon | 23 | 2 | 0 | No | No |
| 18618149 | ORALLY ADMINISTERED COMBINATIONS OF AMOXICILLIN AND AVIBACTAM DERIVATIVES FOR TREATING MYCOBACTERIAL INFECTIONS | March 2024 | February 2026 | Abandon | 23 | 1 | 1 | No | No |
| 18612545 | 2-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18612563 | 2-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18585872 | 3-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | February 2024 | April 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18436833 | 4-CHLORO-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | February 2024 | May 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18412761 | 3-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND | January 2024 | March 2024 | Allow | 2 | 0 | 0 | No | No |
| 18412765 | 3-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-2-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18405453 | TREATMENT OF ALOPECIA AREATA | January 2024 | December 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18545961 | POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION | December 2023 | June 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18531240 | 2-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUND | December 2023 | September 2024 | Abandon | 9 | 1 | 1 | No | No |
| 18501268 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF SAME | November 2023 | February 2026 | Abandon | 28 | 1 | 1 | No | No |
| 18385601 | 3-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18380423 | (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF | October 2023 | March 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18380034 | 4-CHLORO-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18481522 | STAT3 INHIBITORS | October 2023 | September 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18369455 | 1-Deoxynojirimycin To Mitigate Hepatic Ischemia- Reperfusion | September 2023 | May 2025 | Abandon | 20 | 3 | 0 | No | No |
| 18549148 | COMPOSITIONS AND METHODS FOR IMPROVING BRAIN FUNCTION | September 2023 | September 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18241394 | 3-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND | September 2023 | February 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18237543 | 3-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-2-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | February 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18237608 | 2-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-3-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | March 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18353840 | USE OF RILUZOLE PRODRUGS TO TREAT ATAXIAS | July 2023 | July 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18213013 | DEVICES AND METHODS FOR DELIVERY OF OXYGEN TO A WOUND | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18333095 | OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES | June 2023 | December 2025 | Abandon | 30 | 2 | 0 | No | No |
| 18203823 | C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | May 2023 | December 2023 | Allow | 6 | 0 | 1 | Yes | No |
| 18316368 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | May 2023 | January 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18316370 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | May 2023 | January 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18316373 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | May 2023 | January 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18316364 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | May 2023 | February 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18316357 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | May 2023 | February 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18305424 | RelA Inhibitors for Biofilm Disruption | April 2023 | June 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18295654 | TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18188691 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | March 2023 | June 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18187236 | ANALGESIC FORMULATIONS AND METHODS FOR REDUCED POSTOPERATIVE NAUSEA AND VOMITING AND ENHANCED POSTOPERATIVE PAIN RELIEF | March 2023 | March 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18187407 | ANALGESIC FORMULATIONS AND METHODS FOR REDUCED POSTOPERATIVE NAUSEA AND VOMITING AND ENHANCED POSTOPERATIVE PAIN RELIEF | March 2023 | February 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18042010 | MITOCHONDRIA-TARGETED ANTIOXIDANT AS AGENT FOR TREATING PATHOLOGIC INFLAMMATION CAUSED BY MABC-R INFECTION | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | Yes | No |
| 18085842 | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | December 2022 | April 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18080732 | Pyrrolidine Derivative and Use Thereof | December 2022 | March 2025 | Allow | 27 | 2 | 1 | No | No |
| 17937743 | COMPOSITIONS FOR NON-SURGICAL PREVENTION OF BOAR TAINT AND AGGRESSIVE BEHAVIOR | October 2022 | September 2025 | Abandon | 36 | 5 | 1 | No | No |
| 17913471 | 2-BROMO-LYSERGIC ACID DIETHYLAMIDE FOR SUBSTANCE ABUSE | September 2022 | January 2026 | Allow | 40 | 2 | 0 | Yes | No |
| 17905549 | COMPOUNDS FOR USE IN A METHOD OF TREATING, PREVENTING AND/OR REDUCING THE SYMPTOMS OF PAIN | September 2022 | August 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17893122 | C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | August 2022 | March 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 17862656 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | July 2022 | December 2024 | Allow | 30 | 0 | 1 | Yes | No |
| 17838192 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | June 2022 | January 2024 | Allow | 19 | 3 | 1 | Yes | No |
| 17829147 | Nucleotide Analogs | May 2022 | March 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17825777 | THERAPEUTIC METHODS, COMBINATIONS AND KITS | May 2022 | April 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17748351 | COMPOSITIONS AND METHODS FOR INHIBITION OF SARS-COV-2 VIRAL INFECTIONS | May 2022 | February 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17741222 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | May 2022 | February 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17712566 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | April 2022 | April 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17761187 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION | March 2022 | November 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17690889 | GLP-1R MODULATING COMPOUNDS | March 2022 | December 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17686220 | COMPOSITIONS AND METHODS FOR IMPROVING BRAIN FUNCTION | March 2022 | January 2023 | Abandon | 11 | 1 | 1 | No | No |
| 17653056 | THERAPEUTIC COMBINATIONS | March 2022 | May 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17682165 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | February 2022 | June 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17680972 | AGENT FOR TREATING OR PREVENTING CANCER, AND COMBINATION OF RF PATHWAY INHIBITOR AND MEK INHIBITOR FOR TREATING OR PREVENTING CANCER | February 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
| 17637713 | THIXOTROPIC DELIVERY SYSTEMS | February 2022 | February 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17678340 | ACTIVITY OF GOLD-COMPLEXED COMPOUNDS AGAINST MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM ABSCESSUS | February 2022 | January 2026 | Abandon | 47 | 2 | 1 | No | No |
| 17674577 | REMITTIVE EFFECTS OF TAPINAROF IN THE TREATMENT OF PLAQUE PSORIASIS, ATOPIC DERMATITIS, OR RADIATION DERMATITIS | February 2022 | July 2023 | Abandon | 17 | 2 | 1 | No | No |
| 17665553 | METHOD FOR TREATING INFLAMMATION | February 2022 | May 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17560972 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17557429 | BETA-HYDROXYBUTYRATE MIXED SALT COMPOSITIONS AND METHODS OF USE | December 2021 | October 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17619752 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | December 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17529254 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME | November 2021 | January 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17524334 | Nucleotide Analogs | November 2021 | September 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17523806 | Nucleotide Analogs | November 2021 | October 2024 | Allow | 35 | 1 | 0 | No | No |
| 17510108 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | October 2021 | March 2022 | Allow | 5 | 1 | 0 | No | No |
| 17508202 | PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS | October 2021 | March 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17492136 | INTRANASAL DELIVERY OF DIHYDROERGOTAMINE BY PRECISION OLFACTORY DEVICE | October 2021 | April 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17487473 | PAC-1 COMBINATION THERAPY | September 2021 | February 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17483199 | CONTRACEPTIVE REGIMEN INCLUDING REDUCED LEVEL OF ESTROGEN | September 2021 | September 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17447748 | PARENTERAL DOSAGE FORM OF AMIODARONE | September 2021 | October 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17474581 | METHODS OF USING EHMT2 INHIBITORS | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17411903 | SULFATE-FREE CLEANSING COMPOSITION THAT CONFERS HIGH SALICYLIC ACID DEPOSITION | August 2021 | August 2024 | Allow | 36 | 4 | 0 | Yes | No |
| 17393210 | INHIBITION OF MICROSOMAL PROSTAGLANDIN E2 (PGE2) SYNTHASE-1 (MPGES-1) | August 2021 | September 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17378346 | MONO- AND DI-AMIDINE ENDO-EXONUCLEASE INHIBITORS AND METHODS FOR INHIBITING ENDO-EXONUCLEASE ACTIVITY | July 2021 | January 2025 | Allow | 42 | 1 | 1 | No | No |
| 17373296 | Long Acting Multi-Specific Molecules And Related Methods | July 2021 | August 2025 | Allow | 49 | 2 | 1 | Yes | Yes |
| 17368911 | METHODS OF TREATING COVID-19 PATHOGENESIS | July 2021 | November 2024 | Abandon | 40 | 2 | 1 | No | Yes |
| 17365797 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | July 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17357064 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | June 2021 | June 2024 | Allow | 36 | 1 | 0 | No | No |
| 17336951 | NOVEL REGIMES OF FXR AGONISTS | June 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17317235 | METHODS OF TREATING PROSTATE CANCER | May 2021 | May 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17245790 | FUNGICIDAL COMPOSITIONS COMPRISING A CARBOXAMIDE | April 2021 | June 2025 | Allow | 49 | 2 | 1 | No | Yes |
| 17288385 | MUCOADHESIVE PHARMACEUTICAL COMPOSITIONS OF CORTICOSTEROIDS | April 2021 | September 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17238088 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN, OR OTHER PSYCHEDELICS | April 2021 | February 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17228831 | TREATMENT OF ALOPECIA AREATA | April 2021 | January 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17228492 | 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE | April 2021 | January 2024 | Allow | 33 | 1 | 0 | No | No |
| 17210874 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | March 2021 | February 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17207346 | LOW BENZALKONIUM CHLORIDE BIMATOPROST OPHTHALMIC COMPOSITIONS WITH EFFECTIVE PENETRATION & PRESERVATION PROPERTIES | March 2021 | October 2022 | Allow | 19 | 4 | 0 | No | No |
| 17198634 | BETA-HYDROXYBUTYRATE MIXED SALT COMPOSITIONS AND METHODS OF USE | March 2021 | November 2021 | Allow | 8 | 1 | 1 | No | No |
| 17199136 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SEIZURE-RELATED DISORDERS | March 2021 | January 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17166689 | USES OF A LYSYL OXIDASE-LIKE 2 INHIBITOR | February 2021 | September 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17166778 | METHOD OF TREATMENT FOR REDUCING PAIN SENSITIZATION | February 2021 | March 2026 | Abandon | 60 | 4 | 1 | No | No |
| 17263662 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | January 2021 | September 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17263488 | METHOD OF TREATING AGGRESSION WITH OREXIN RECEPTOR ANTAGONISTS | January 2021 | March 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17148785 | Azetidine Derivatives | January 2021 | October 2024 | Allow | 45 | 2 | 1 | No | No |
| 17139299 | CGRP RECEPTOR ANTAGONISTS | December 2020 | August 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17136674 | POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION | December 2020 | September 2023 | Allow | 33 | 1 | 0 | No | No |
| 17256066 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | December 2020 | October 2023 | Allow | 34 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COPPINS, JANET L.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COPPINS, JANET L works in Art Unit 1628 and has examined 489 patent applications in our dataset. With an allowance rate of 69.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 27 months.
Examiner COPPINS, JANET L's allowance rate of 69.5% places them in the 31% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by COPPINS, JANET L receive 1.87 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by COPPINS, JANET L is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +34.0% benefit to allowance rate for applications examined by COPPINS, JANET L. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.7% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 28.9% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 57.4% are granted (fully or in part). This grant rate is in the 60% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.1% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.